Jefferies Group’s Pacira BioSciences PCRX Stock Holding History

Jefferies Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.05M	Hold	38,500	–	–	0.02%	603
2022 Q2	$2.24M	Buy	+38,500	New	+$2.52M	0.02%	583
2021 Q1	–	Sell	-16,800	Closed	-$1.01M	–	1892
2020 Q4	$1.01M	Hold	16,800	–	–	0.01%	945
2020 Q3	$1.01M	Buy	+16,800	New	+$976K	0.01%	793
2020 Q2	–	Sell	-200,000	Closed	-$6.71M	–	1871
2020 Q1	$6.71M	Buy	+200,000	New	+$8.31M	0.07%	231
2019 Q3	–	Sell	-70,000	Closed	-$3.04M	–	2948
2019 Q2	$3.04M	Buy	70,000 +40,000	+133%	+$1.7M	0.02%	713
2019 Q1	$1.14M	Sell	30,000 -34,400	-53%	-$1.34M	0.01%	1203
2018 Q4	$2.77M	Sell	64,400 -4,900	-7%	-$229K	0.02%	668
2018 Q3	$3.41M	Buy	+69,300	New	+$3M	0.02%	723
2016 Q4	–	Sell	-10,000	Closed	-$342K	–	2407
2016 Q3	$342K	Sell	10,000 -3,000	-23%	-$118K	﹤0.01%	1764
2016 Q2	$438K	Buy	13,000 +10,000	+333%	+$491K	﹤0.01%	1507
2016 Q1	$159K	Sell	3,000 -27,000	-90%	-$1.58M	﹤0.01%	1892
2015 Q4	$2.3M	Buy	30,000 +25,000	+500%	+$1.42M	0.01%	815
2015 Q3	$206K	Hold	5,000	–	–	﹤0.01%	1921
2015 Q2	$354K	Buy	+5,000	New	+$394K	﹤0.01%	1716

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Jefferies Group's PCRX Position: Q3 2022 in Review

Jefferies Group increased its Pacira BioSciences (PCRX) stake by 299% in Q3 2022, buying an estimated $1.25M and bringing the position to 29,954 shares worth $1.59M. The position accounts for 0.01% of the portfolio, ranked #678.

Jefferies Group first reported a position in PCRX in Q2 2013 and has held it in 27 quarters since. The position peaked at $6.55M in Q1 2020. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Jefferies Group held 29,954 shares of Pacira BioSciences worth $1.59M as of Q3 2022.
Jefferies Group bought 22,454 Pacira BioSciences shares in Q3 2022, an estimated $1.25M.
Pacira BioSciences made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #678 holding.
Jefferies Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 27 quarters since.
Jefferies Group's Pacira BioSciences position peaked at $6.55M in Q1 2020.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.